Loading...
XLON
DEMG
Market cap861kUSD
Feb 20, Last price  
0.02GBP
Name

Deltex Medical Group PLC

Chart & Performance

D1W1MN
P/E
P/S
37.37
EPS
Div Yield, %
Shrs. gr., 5y
20.16%
Rev. gr., 5y
-18.55%
Revenues
2m
-28.44%
2,494,0003,042,0003,511,0004,168,0005,235,0005,640,0006,279,0006,303,0006,777,0007,151,0006,507,0006,405,0006,331,0005,870,0004,955,0004,256,0002,398,0002,259,0002,482,0001,776,000
Net income
-1m
L+11.58%
-2,754,000-1,749,000-1,994,000-2,188,000-2,557,000-1,988,000-1,468,000-1,421,000-2,093,000-2,106,000-2,951,000-3,460,000-2,376,000-2,001,000-1,264,000-161,000-798,000-967,000-1,149,000-1,282,000
CFO
-1m
L+97.19%
-1,887,000-1,269,000-1,545,000-2,129,000-2,387,000-1,769,000-790,000-1,352,000-1,109,000-1,418,000-1,803,000-1,688,000-1,816,000-928,000-1,318,000609,000-68,000-291,000-606,000-1,195,000
Earnings
May 08, 2025

Profile

Deltex Medical Group plc, together with its subsidiaries, manufactures, markets, and sells oesophageal doppler haemodynamic monitoring systems under the TrueVue name in the United Kingdom, the United States, Spain, Canada, and internationally. It offers esophageal Doppler Probes that is used to measure a patient's central vascular blood flow and fluid status to measure real time blood velocities within the descending aorta; Loops plots aortic blood flow velocity and aortic blood pressure monitoring throughout every heartbeat; High Definition Impedance Cardiography, a non-invasive cardiac function and fluid status monitoring system for awake patients; and PressureWave, a pulse pressure waveform analysis algorithm used during periods of instability or for periods when the ODM mode is unavailable. The company also provides Deltex Medical Esophageal Doppler Simulator that enables clinicians to practice probe insertion, focusing, and waveform interpretation outside of a patient setting. Its products are used in Covid-19 critical care; sepsis; major abdominal, laparoscopic, and spinal surgeries; cardiac, trauma, and transplant procedures; and post-operative acute kidney injury monitoring. Deltex Medical Group plc was incorporated in 2000 and is headquartered in Chichester, the United Kingdom.
IPO date
Aug 20, 2001
Employees
44
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,776
-28.44%
2,482
9.87%
Cost of revenue
2,634
3,513
Unusual Expense (Income)
NOPBT
(858)
(1,031)
NOPBT Margin
Operating Taxes
(83)
(72)
Tax Rate
NOPAT
(775)
(959)
Net income
(1,282)
11.58%
(1,149)
18.82%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,887
1,225
BB yield
-110.17%
-17.87%
Debt
Debt current
137
987
Long-term debt
1,961
1,246
Deferred revenue
Other long-term liabilities
71
241
Net debt
1,393
1,598
Cash flow
Cash from operating activities
(1,195)
(606)
CAPEX
(9)
(744)
Cash from investing activities
(370)
(744)
Cash from financing activities
1,786
1,413
FCF
(1,065)
(964)
Balance
Cash
705
471
Long term investments
164
Excess cash
616
511
Stockholders' equity
(32,507)
(31,444)
Invested Capital
37,642
35,811
ROIC
ROCE
EV
Common stock shares outstanding
1,181,215
685,491
Price
0.00
-85.50%
0.01
-29.82%
Market cap
1,713
-75.01%
6,855
-17.16%
EV
2,960
8,332
EBITDA
(725)
(903)
EV/EBITDA
Interest
230
199
Interest/NOPBT